English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse
  1. Start / 
  2. Item Summary

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance

MPS-Authors
/persons/resource/persons38744

Acker-Palmer,  Amparo
Neurovascular interface Group, Max Planck Institute for Brain Research, Max Planck Society;

External Resource

https://www.ncbi.nlm.nih.gov/pubmed/27470974
(Any fulltext)

Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Depner, C., Zum Buttel, H., Bogurcu, N., Cuesta, A. M., Aburto, M. R., Seidel, S., et al. (2016). EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance. Nat Commun, 7, 12329. doi:10.1038/ncomms12329.


Cite as: https://hdl.handle.net/21.11116/0000-0008-0C0E-D
Abstract
Diffuse invasion of the surrounding brain parenchyma is a major obstacle in the treatment of gliomas with various therapeutics, including anti-angiogenic agents. Here we identify the epi-/genetic and microenvironmental downregulation of ephrinB2 as a crucial step that promotes tumour invasion by abrogation of repulsive signals. We demonstrate that ephrinB2 is downregulated in human gliomas as a consequence of promoter hypermethylation and gene deletion. Consistently, genetic deletion of ephrinB2 in a murine high-grade glioma model increases invasion. Importantly, ephrinB2 gene silencing is complemented by a hypoxia-induced transcriptional repression. Mechanistically, hypoxia-inducible factor (HIF)-1alpha induces the EMT repressor ZEB2, which directly downregulates ephrinB2 through promoter binding to enhance tumour invasiveness. This mechanism is activated following anti-angiogenic treatment of gliomas and is efficiently blocked by disrupting ZEB2 activity. Taken together, our results identify ZEB2 as an attractive therapeutic target to inhibit tumour invasion and counteract tumour resistance mechanisms induced by anti-angiogenic treatment strategies.